Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

TitlePharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.
Publication TypeJournal Article
Year of Publication2006
AuthorsAberg JA, Rosenkranz SL, Fichtenbaum CJ, Alston BL, Brobst SW, Segal Y, Gerber JG
Corporate AuthorsACTG A5108 team
JournalAIDS
Volume20
Issue5
Pagination725-9
Date Published2006 Mar 21
ISSN0269-9370
KeywordsAdult, Area Under Curve, Drug Administration Schedule, Drug Interactions, Female, HIV Protease Inhibitors, HIV Seronegativity, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Nelfinavir, Pravastatin, Time Factors, Volunteers
Abstract

BACKGROUND: Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia.

OBJECTIVE: To examine the effect of nelfinavir on pravastatin pharmacokinetics.

DESIGN: Open-label study in healthy HIV-seronegative adults conducted at the AIDS Clinical Trials Group sites in the United States.

METHODS: Subjects received pravastatin 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Subjects took only nelfinavir 1250 mg twice daily on days 4-12. On days 13-15, subjects continued nelfinavir and reinitiated pravastatin. Plasma samples were collected over 24 h for the calculation of pravastatin area under the concentration-time curve for 0-24 h on days 3 and 16.

RESULTS: Data from 14 subjects with complete pharmacokinetic samples were available for analysis. The median within-subject percentage change in pravastatin AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were also lower when pravastatin was administered with nelfinavir. Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%.

CONCLUSIONS: Coadministration of pravastatin and nelfinavir led to a substantial reduction in pravastatin plasma concentrations. Higher doses of pravastatin may need to be prescribed in order to achieve optimal lipid-lowering activity.

DOI10.1097/01.aids.0000216373.53819.92
Alternate JournalAIDS
PubMed ID16514303
PubMed Central IDPMC1459289
Grant ListAI -27665 / AI / NIAID NIH HHS / United States
AI-25897 / AI / NIAID NIH HHS / United States
AI-27658 / AI / NIAID NIH HHS / United States
AI-27666 / AI / NIAID NIH HHS / United States
AI-32770 / AI / NIAID NIH HHS / United States
AI-38855 / AI / NIAID NIH HHS / United States
AI-38858 / AI / NIAID NIH HHS / United States
M01-RR00070 / RR / NCRR NIH HHS / United States
U01 AI027665 / AI / NIAID NIH HHS / United States